Page last updated: 2024-08-26

yttrium radioisotopes and Carcinoma, Ductal, Pancreatic

yttrium radioisotopes has been researched along with Carcinoma, Ductal, Pancreatic in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Alexander, HC; Bartlett, ASJR; Chu, MJJ; Han, CH; Holden, AH; Nguyen, CH; Tarr, GP; Thomas, RH	1
Kim, AY; Pishvaian, MJ; Unger, K; Wang, H	1
Bekaii-Saab, T; Gold, DV; Goldenberg, DM; Goldsmith, SJ; Guarino, MJ; Gulec, SA; Hall, N; Holt, M; Horne, H; Kauh, J; Lee, D; Manzone, T; Montero, AJ; O'Neil, BH; Ocean, AJ; Pennington, KL; Serafini, AN; Sheikh, A; Sung, MW; Wegener, WA	1

Reviews

1 review(s) available for yttrium radioisotopes and Carcinoma, Ductal, Pancreatic

Article	Year
Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review. Journal of vascular and interventional radiology : JVIR, 2022, Volume: 33, Issue:12 Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Embolization, Therapeutic; Humans; Liver Neoplasms; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes	2022

Article

Year

Transarterial Radioembolization for Hepatic Metastases of Pancreatic Adenocarcinoma: A Systematic Review.

Journal of vascular and interventional radiology : JVIR, 2022, Volume: 33, Issue:12

Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Embolization, Therapeutic; Humans; Liver Neoplasms; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes

2022

Trials

1 trial(s) available for yttrium radioisotopes and Carcinoma, Ductal, Pancreatic

Article	Year
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer, 2012, Nov-15, Volume: 118, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes	2012

Article

Year

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.

Cancer, 2012, Nov-15, Volume: 118, Issue:22

Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes

2012

Other Studies

1 other study(ies) available for yttrium radioisotopes and Carcinoma, Ductal, Pancreatic

Article	Year
Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience. BMC cancer, 2016, 07-18, Volume: 16 Topics: Aged; Carcinoma, Pancreatic Ductal; Catheter Ablation; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Ducts; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Yttrium; Yttrium Radioisotopes	2016

Article

Year

Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience.

BMC cancer, 2016, 07-18, Volume: 16

Topics: Aged; Carcinoma, Pancreatic Ductal; Catheter Ablation; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Ducts; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Yttrium; Yttrium Radioisotopes

2016